Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction
of Near-Term Rehospitalization in Patients With Heart Failure
WALTHAM, Mass., March 25, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) announced today the publication of results, in the American
Heart Journal, of an analysis of aggregated data from three large, multicenter
clinical research trials in the United States and Europe. The trials included
a total of 902 heart failure patients and demonstrated that elevations of
galectin-3 levels in blood, as measured using the BGM Galectin-3® Test, were
significantly predictive of rehospitalization for heart failure as early as
within the first 30 days following discharge from an initial hospital stay.
The authors reported that heart failure patients with elevations in their
galectin-3 levels at the time of their hospitalization were re-admitted within
30 days at nearly three times the rate of patients without galectin-3
elevation (risk ratio of 2.80 at 30 days, P-value of 0.003). The increased
risk conferred by elevations in galectin-3 was seen to persist at 60, 90 and
120 days in the study. Galectin-3 testing correctly identified markedly higher
risk among between one-fifth to one-third of all patients who, based on
conventional risk assessment, were placed into a low risk category at the time
of their initial hospital discharge but who, nonetheless, went on to be
rehospitalized or suffer a fatal event (net reclassification improvement
statistic value of +42.6% at 30 days, P-value < 0.001).
In the United States, the annual cost to Medicare of hospital readmissions
within 30 days of discharge has been estimated to exceed $17 billion.  The
leading cause of hospital readmissions among Medicare beneficiaries is heart
failure related complications.  The recently enacted Affordable Care Act
required the Centers for Medicare and Medicaid to implement penalty-based
reductions in payments to hospitals with excessive rates of readmissions
within 30 days of hospital discharge. The Medicare Payment Advisory Commission
has concluded that approximately three-quarters of these hospital readmissions
are potentially preventable. 
"We believe that this analysis of data from three significant clinical
research trials further affirms the previously reported utility of galectin-3
testing as an aid in assessing the prognosis of patients with heart failure
when used in conjunction with clinical evaluation," said Dr. Paul R. Sohmer,
President and CEO of BG Medicine, Inc. "The identification of heart failure
patients who are at significantly elevated risk for unforeseen events may
facilitate the care of heart failure patients and help control the cost burden
of this disease on healthcare systems worldwide."
The BGM Galectin-3® Test is cleared by the U.S. FDA as an aid in assessing the
prognosis of patients diagnosed with chronic heart failure when used in
conjunction with clinical evaluation.
The BGM Galectin-3® Test is CE Marked and is available in Europe as an aid in
assessing the prognosis of patients diagnosed with acute and chronic heart
failure when used in conjunction with clinical evaluation. It is also CE
Marked for adults as an aid in assessing the risk of new onset heart failure.
About Galectin-3 and Heart Failure
Galectin-3 is a protein that is involved in fundamental disease processes
including the development of fibrosis in organ tissues, and cardiac
remodeling, which may lead to the development and progression of heart
failure. Higher levels of galectin-3 are associated with a more aggressive
form of heart failure, which may make identification of high-risk patients
using galectin-3 testing an important part of patient care. Galectin-3 testing
may be useful in helping physicians determine which patients are at higher
risk of hospitalization or death. The BGM Galectin-3® Test is to be used as an
aid in assessing the prognosis of patients with chronic heart failure, in
conjunction with clinical evaluation. For more information please visit
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is
focused on the development and delivery of diagnostic solutions to aid in the
clinical management of heart failure and related disorders. For additional
information about BG Medicine, heart failure and galectin-3 testing, please
The BG Medicine Inc. logo is available for download here
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding: our belief that this analysis further
affirms the previously reported utility of galectin-3 testing; and our belief
that the identification of heart failure patients who are at significantly
elevated risk for unforeseen events may facilitate the care of heart failure
patients and help control the cost burden on healthcare systems worldwide.
These forward-looking statements are neither promises nor guarantees of future
performance, and are subject to a variety of risks and uncertainties, many of
which are beyond the Company's control, which could cause actual results to
differ materially from those contemplated in these forward-looking statements.
These risks and uncertainties include, among other things, the factors
discussed under the heading "Risk Factors" contained in BG Medicine's annual
report and quarterly reports filed with the Securities and Exchange
Commission. All information in this press release is as of the date of the
release, and BG Medicine disclaims any obligation to update the information
contained in this press release as new information becomes available.
1. Meijers WC, Januzzi JL, deFilippi C, et al. Elevated Plasma Galectin-3 is
Associated with Near-Term Rehospitalization in Heart Failure: A Pooled
Analysis of 3 Clinical Trials. American Heart Journal (2014),
2. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in
the Medicare fee-for-service program. N Engl J Med. 2009 Apr
3. Medicare Payment Advisory Commission. A path to bundled payment around a
rehospitalization. In: Report to the Congress: reforming the delivery system.
Washington, DC:, June 2005:83-103.
CONTACT: Corporate Communications
+1 (781) 890-1199
BG Medicine, Inc.
BG Medicine, Inc. logo
Press spacebar to pause and continue. Press esc to stop.